Using this assay, we showed that PTEN loss is associated with PTEN gene deletion [24], and independently associated with an increased risk of biochemical recurrence [7, 25] and lethal prostate cancer [13] in several large, multi-institutional cohorts of patients largely treated by radical prostatectomy. The gene discussed is PTEN; the disease is prostate cancer.